TuisGRAL • NASDAQ
add
Grail Inc
Vorige sluiting
$38,65
Dagwisseling
$36,87 - $38,47
Jaarwisseling
$12,33 - $63,99
Markkapitalisasie
1,37 mjd USD
Gemiddelde volume
794,20 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 35,54 m | 11,18% |
Bedryfskoste | 146,55 m | -37,88% |
Netto inkomste | -113,98 m | 92,81% |
Netto winsgrens | -320,69 | 93,53% |
Wins per aandeel | -3,18 | — |
EBITDA | -91,68 m | 49,34% |
Effektiewe belastingkoers | 25,43% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 602,75 m | -37,14% |
Totale bates | 2,70 mjd | -17,34% |
Totale aanspreeklikheid | 387,91 m | -32,48% |
Totale ekwiteit | 2,31 mjd | — |
Uitstaande aandele | 36,05 m | — |
Prys om te bespreek | 0,60 | — |
Opbrengs op bates | -11,79% | — |
Opbrengs op kapitaal | -13,48% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -113,98 m | 92,81% |
Kontant van bedrywe | -76,96 m | 55,20% |
Kontant van beleggings | 70,37 m | 5 177,13% |
Kontant van finansiering | — | — |
Netto kontantverandering | -6,47 m | -100,85% |
Beskikbare kontantvloei | -29,88 m | 75,95% |
Meer oor
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.
Grail was spun-out from Illumina on June 24, 2024.
Their liquid biopsy was launched in June 2021 and is called the Galleri test. Wikipedia
Gestig
2015
Webwerf
Werknemers
1 000
